|Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40.|
|Jump to Full Text|
|PMID: 19066610 Owner: NLM Status: MEDLINE|
|SGN-40 is a therapeutic antibody targeting CD40, which induces potent anti-lymphoma activities via direct apoptotic signalling cells and by cell-mediated cytotoxicity. Here we show antibody-dependent cellular phagocytosis (ADCP) by macrophages to contribute significantly to the therapeutic activities and that the antitumour effects of SGN-40 depend on Fc interactions.|
|E Oflazoglu; I J Stone; L Brown; K A Gordon; N van Rooijen; M Jonas; C-L Law; I S Grewal; H-P Gerber|
|Type: Journal Article Date: 2008-12-09|
|Title: British journal of cancer Volume: 100 ISSN: 1532-1827 ISO Abbreviation: Br. J. Cancer Publication Date: 2009 Jan|
|Created Date: 2009-01-07 Completed Date: 2009-01-30 Revised Date: 2010-09-22|
Medline Journal Info:
|Nlm Unique ID: 0370635 Medline TA: Br J Cancer Country: England|
|Languages: eng Pagination: 113-7 Citation Subset: IM|
|Department of Preclinical Therapeutics, Seattle Genetics Inc., Seattle, WA 98021, USA.|
|APA/MLA Format Download EndNote Download BibTex|
Antibodies, Monoclonal / pharmacology*
Antigens, CD40 / immunology*
Antineoplastic Agents / pharmacology*
Cell Line, Tumor
Lymphoma / drug therapy*
Macrophages / immunology*
Receptors, Fc / physiology*
|0/Antibodies, Monoclonal; 0/Antigens, CD40; 0/Antineoplastic Agents; 0/Receptors, Fc|
Journal ID (nlm-ta): Br J Cancer
Publisher: Nature Publishing Group
Copyright 2009, Cancer Research UK
Received Day: 17 Month: 10 Year: 2008
Revision Received Day: 12 Month: 11 Year: 2008
Accepted Day: 13 Month: 11 Year: 2008
Electronic publication date: Day: 09 Month: 12 Year: 2008
collection publication date: Day: 06 Month: 01 Year: 2009
Print publication date: Day: 13 Month: 01 Year: 2009
Volume: 100 Issue: 1
First Page: 113 Last Page: 117
Publisher Item Identifier: 6604812
PubMed Id: 19066610
|Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40|
|I J Stone1|
|K A Gordon1|
|N van Rooijen3|
|I S Grewal1|
1Department of Preclinical Therapeutics, Seattle Genetics Inc. Seattle, WA 98021, USA
2Department of Antibody Technologies, Seattle Genetics Inc. Seattle, WA 98021, USA
3Department of Molecular Cell Biology, Vrije Universiteit Amsterdam, The Netherlands
|*Author for correspondence: email@example.com
CD40 is a member of the tumour necrosis factor (TNF) receptor superfamily and is expressed predominantly on haematopoietic cells, including B-cells, dendritic cells, monocytes, macrophages, activated B-cells and CD8+ T-cells (reviewed in van Kooten and Banchereau (2000)). In lymphoid malignancies, CD40 is present on B-cell precursor acute lymphoblastic leukaemia (ALL (Uckun et al, 1990)), non-Hodgkin's lymphoma (NHL (Uckun et al, 1990)), Hodgkin's lymphoma (HL (O'Grady et al, 1994)) and multiple myeloma (MM (Westendorf et al, 1994)).
The humanised monoclonal antibody targeting CD40 (SGN-40) induces potent antitumour effects when tested on CD40-positive tumour cell lines representing a variety of haematologic malignancies (Tai et al, 2004; Law et al, 2005). The mechanisms mediating the antitumour activity of SGN-40 include direct cytotoxic signalling, inducing caspase-3 activation and apoptosis of tumour cells (Law et al, 2005; Tai et al, 2005) and natural killer (NK) cell-mediated ADCC. Both, direct cell killing and NK cell-mediated ADCC are enhanced by antibody crosslinking (Law et al, 2005) when tested in vitro. However, the mechanism involved in mediating anti-lymphoma activity of SGN-40 in vivo remained to be investigated.
The ability of several human IgG1-type therapeutic antibodies to engage human effector cells varies significantly, depending on the target antigen and tumour type, and variable degrees of tumour cell death induced by NK cells, neutrophils and macrophages were reported for anti-CD19, -20 and -70 antibodies (reviewed in Tedder et al (2006)). Here we show for the first time that macrophages contribute significantly to the antitumour effects of SGN-40 when tested in models of human lymphoma. In addition, a mutant form of SGN-40, lacking Fc-receptor interactions (SGN40-IgG1v1), lacked therapeutic activity when tested in vitro and in mice implanted with B-cell lymphomas. The important role of macrophages in mediating therapeutic activity described here may help to guide the clinical development of SGN-40 for the treatment of B-cell malignancies.
The CD40-positive lymphoma cell lines Ramos (NHL, Burkitt's lymphoma) and WIL2-S (B-cell lymphoma) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The CD40-negative cell line L540cy was kindly provided by Dr Phil Thorpe (University of Texas, Southwestern Medical School, Dallas, TX, USA). Cells were grown in RPMI (Life Technologies Inc., Gaithersburg, MD, USA) supplemented with 20% fetal bovine serum (FBS).
The anti-CD40 variant containing the mutations, E233P:L234V:L235A (Armour et al, 1999) (SGN-40G1v1) was generated using the Quikchange Site-Directed Mutagenesis system (Stratagene, La Jolla, CA, USA). The SGN-40 variant heavy chain and SGN-40 light chain were each cloned into the expression vector pDEF38 (Running Deer and Allison, 2004) downstream of the CHEF EF-1α promoter and stably expressed in CHO-DG44 (Urlaub et al, 1986) cells. SGN-40 and SGN-40G1v1 proteins were expressed in CHO-DG44 cell lines and purified by protein A chromatography. Complementary DNA clones for human (hu) FcγRI (IMAGE clone 5248549), huFcγRIIIA V158 (IMAGE clone 5206097) and huFcɛR γ chain (IMAGE clone 5219148) were obtained from Invitrogen (Carlsbad, CA, USA) and coding regions were introduced into a mammalian expression vector system. Proteins were expressed in CHO-DG44 cell lines and highly expressing clones were selected by FACS and recovered by limited dilution cloning. Preliminary pharmacokinetic analysis of serum samples from treated mice revealed comparable characteristics between SGN-40 and SGN-40G1v1 (data not shown).
SGN-40 was labelled with Alexa Fluor 488 carboxylic acid–succinimidyl ester conjugation using the Invitrogen Alexa Fluor 488 labeling kit (Invitrogen). For binding experiments, Ramos or stable CHO DG-44 cells expressing huFcγRI and huFcγRIIIA V158 were mixed and combined with serial dilutions of SGN-40 or the SGN-40G1v1 variant. Labelled cells were detected using an LSRII FACS analyzer (Beckton Dickinson Biosciences, San Jose, CA, USA). The flow cytometry data was analysed with a one site competition model equation using Prism v4.01 (GraphPad Software, San Diego, CA, USA).
The assay was performed as described earlier (McEarchern et al, 2007). Briefly, after labelling of CD40-positive target cells (Ramos), cells were pre-coated with SGN-40 or SGN-40G1v1 and incubated with monocyte-derived macrophages. The purity of the macrophage preparations were routinely >95% (data not shown).
Tumour bearing CB-17/lcr SCID mice were depleted of effector cells by using anti-asialo-GM 1 (1.25 mg kg−1, neutrophils) and anti-Gr-1 (4 mg kg−1, NK cells) clodronate encapsuled liposomes (CEL, macrophage), as described earlier (Oflazoglu et al, 2007). For IHC analysis, liver and spleen sections were stained with an anti-mouse F4/80 (macrophage marker) (AbD Serotec, Oxford, UK) using the Bondmax autostainer (Leica Microsystems Inc., Bannockburn, IL, USA) with an alkaline phosphatase-fast red detection kit. Mice were monitored at least twice per week and were sacrificed when they exhibited signs of disease, including weight loss of 15–20%, hunched posture, lethargy, cranial swelling or dehydration. Statistical analysis was conducted using the log-rank test with the Graphpad Prism Software Package version 4.01 (Graphpad). All animal experiments were performed according to the guidelines of the Institutional Animal Care and Use Committee (IACUC).
To study the contributions of Fc-receptor interactions to the antitumour activity of SGN-40, we constructed an Fc variant form of SGN-40 containing a substitution of three amino acids in the Fc portion of the γ1 heavy chain (SGN-40G1v1). When introduced to other therapeutic MAbs of the IgG1 isotype, these changes resulted in abolished Fc-receptor interactions (Armour et al, 1999). As expected, no changes in the ability of SGN-40 and SGN-40G1v1 to bind to CD40 were observed (Figure 1A). However, competition binding assays with cells expressing human or mouse CD16 (FcγRIII) and CD64 (FcγRI) confirmed that SGN-40G1v1 lacked binding affinity to Fc receptors (Figure 1B). For SGN-40, weaker binding to mouse relative to human CD64 (FcγR1) and lack of binding to mouse CD16 (FcγRIII) were also noticed. Although Fcγ-receptor interactions are essential for effector cell activation, no direct correlation between binding affinities of therapeutic antibodies and activation of effector cells were reported (Richards et al, 2008), because these responses are ultimately regulated by the balance between activating and inhibitory signals delivered through Fcγ receptors. Therefore, the differences in binding affinity of SGN-40 between Fcγ-RI+III are not predictive for antitumour activities in vivo.
To determine the levels of antibody-dependent cellular phagocytosis (ADCP) engagement, SGN-40 and SGN-40G1v1 were incubated in presence of primary human monocytic cells and tested for their ability to induce phagocytosis of CD40+ Ramos (Burkitt's lymphoma, Figures 1C and D) and WIL2-S cells (B-cell lymphoma, Figure 1D) by macrophages. Although SGN-40 induced robust ADCP, SGN-40G1v1 was devoid of detectable ADCP activity, showing that Fc–Fcγ-receptor interactions are necessary for phagocytic uptake of target lymphoma cells (Figure 1D). These studies show that Fc-dependent ADCP may represent an important mechanism by which SGN-40 induces anti-lymphoma effects.
To investigate the relevance of Fc–FcγR interactions for overall therapeutic activity, we compared survival of tumour bearing mice treated with either SGN-40 or SGN-40G1v1. In contrast to SGN-40, SGN-40G1v1 did not delay disease progression relative to untreated mice (Figure 1E). These findings indicate that all mechanisms contributing to anti-lymphoma activities by SGN-40 are dependent on Fc interactions in this NHL model, including direct apoptotic signalling in tumour cells. Next, we were interested to identify the identity of the effector cells mediating the antitumour activity of SGN-40 in vivo. For this purpose, tumour-bearing mice were selectively depleted of either NK cells (Figure 2A), neutrophils (Figure 2B), macrophages (Figure 2C) or all three cell types combined (Figure 2D). Although the lack of NK cells and neutrophils did not significantly affect the antitumour activity of SGN-40, depletion of macrophages, either alone or combined with NK and neutrophil cells, resulted in decreased survival of tumour-bearing mice compared with non-effector cell ablated animals (Figures 2C and D, P=0.0016 and 0.0004, respectively). These findings are in agreement with an earlier report showing potent antitumour activity of SGN-40 in SCID-beige mice, which display impaired NK cell functions (Law et al, 2005). Antitumour activity was evident in macrophage ablated mice (Figure 2C), suggesting that non-macrophage-dependent mechanisms may contribute to the in vivo activity in this model, including direct apoptotic signalling in tumour cells. The degree of effector cell depletion was monitored by FACS or IHC analysis (Figure 2E). Robust target effector cell depletion was confirmed by flow cytometric analysis of splenocytes (NK cells, anti-DX5), peripheral blood (neutrophils, anti-CD11b) or by F4/80-IHC staining (macrophages) in liver sections.
In humans, macrophages express all three Fcγ receptors, whereas neutrophils and NK cells express predominantly FcγRII and FcγRIII (Koene et al, 1997). Sequence nucleotide polymorphisms within the FCGR2 and FCGR3 loci in humans alter their binding affinities to IgG1 Mabs, and ultimately impact on downstream effector cell engagement of therapeutic Mabs such as the anti-CD20 antibody Rituximab (Weng and Levy, 2003). In addition, the contributions of effector cells to antitumour effects of therapeutic MAbs were shown to vary between tumour types. For example, FcγR II+III single nucleotide polymorphisms (SNPs) correlated with therapeutic activity of rituximab in NHL, but not in CLL patients (Cartron et al, 2002; Weng and Levy, 2003; Farag et al, 2004). Combined, these findings suggest that the analysis of patient Fcγ-receptor polymorphisms and comparison with clinical response rates may provide important information regarding the mechanism of action employed by SGN-40 in different heme-malignancies, including NHL and MM. Importantly, the chemotherapy agents used for the treatment of NHL were shown to interfere differentially with macrophage functions (Marcus and Hagenbeek, 2007). Given the important role of macrophages in mediating the therapeutic activity of SGN-40 described in this report, it is tempting to speculate that combining SGN-40 with therapeutic agents that enhance macrophage activities, including Revlimid in MM indications, may be beneficial.
We thank Kim Kissler and Weiping Zeng for their help with conducting the animal experiments, Drs Paul Carter and Django Sussman for help in antibody engineering. Drs Tim Lewis, Gerald Neslund for their expert advice in the design of the studies and Mark Sandbaken for critical reading of the manuscript.
|Armour KL,Clark MR,Hadley AG,Williamson LM. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activitiesEur J Immunol 1999;29:2613–2624. [pmid: 10458776]|
|Cartron G,Dacheux L,Salles G,Solal-Celigny P,Bardos P,Colombat P,Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa geneBlood 2002;99:754–758. [pmid: 11806974]|
|Farag SS,Flinn IW,Modali R,Lehman TA,Young D,Byrd JC. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemiaBlood 2004;103:1472–1474. [pmid: 14563637]|
|Koene HR,Kleijer M,Algra J,Roos D,von dem Borne AE,de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotypeBlood 1997;90:1109–1114. [pmid: 9242542]|
|Law CL,Gordon KA,Collier J,Klussman K,McEarchern JA,Cerveny CG,Mixan BJ,Lee WP,Lin Z,Valdez P,Wahl AF,Grewal IS. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40Cancer Res 2005;65:8331–8338. [pmid: 16166310]|
|Marcus R,Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphomaEur J Haematol Suppl 2007;67:5–14. [pmid: 17206982]|
|McEarchern JA,Oflazoglu E,Francisco L,McDonagh CF,Gordon KA,Stone I,Klussman K,Turcott E,van Rooijen N,Carter P,Grewal IS,Wahl AF,Law CL. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activitiesBlood 2007;109:1185–1192. [pmid: 17038522]|
|O'Grady JT,Stewart S,Lowrey J,Howie SE,Krajewski AS. CD40 expression in Hodgkin's diseaseAm J Pathol 1994;144:21–26. [pmid: 7507299]|
|Oflazoglu E,Stone IJ,Gordon KA,Grewal IS,van Rooijen N,Law CL,Gerber HP. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30Blood 2007;110:4370–4372. [pmid: 17909075]|
|Richards JO,Karki S,Lazar GA,Chen H,Dang W,Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cellsMol Cancer Ther 2008;7:2517–2527. [pmid: 18723496]|
|Running Deer J,Allison DS. High-level expression of proteins in mammalian cells using transcription regulatory sequences from the Chinese hamster EF-1alpha geneBiotechnol Prog 2004;20:880–889. [pmid: 15176895]|
|Tai YT,Catley LP,Mitsiades CS,Burger R,Podar K,Shringpaure R,Hideshima T,Chauhan D,Hamasaki M,Ishitsuka K,Richardson P,Treon SP,Munshi NC,Anderson KC. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implicationsCancer Res 2004;64:2846–2852. [pmid: 15087402]|
|Tai YT,Li XF,Catley L,Coffey R,Breitkreutz I,Bae J,Song W,Podar K,Hideshima T,Chauhan D,Schlossman R,Richardson P,Treon SP,Grewal IS,Munshi NC,Anderson KC. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implicationsCancer Res 2005;65:11712–11720. [pmid: 16357183]|
|Tedder TF,Baras A,Xiu Y. Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunitySpringer Semin Immunopathol 2006;28:351–364. [pmid: 17091246]|
|Uckun FM,Gajl-Peczalska K,Myers DE,Jaszcz W,Haissig S,Ledbetter JA. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cellsBlood 1990;76:2449–2456. [pmid: 1702326]|
|Urlaub G,Mitchell PJ,Kas E,Chasin LA,Funanage VL,Myoda TT,Hamlin J. Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversionsSomat Cell Mol Genet 1986;12:555–566. [pmid: 3024331]|
|van Kooten C,Banchereau J. CD40-CD40 ligandJ Leukoc Biol 2000;67:2–17. [pmid: 10647992]|
|Weng WK,Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphomaJ Clin Oncol 2003;21:3940–3947. [pmid: 12975461]|
|Westendorf JJ,Ahmann GJ,Armitage RJ,Spriggs MK,Lust JA,Greipp PR,Katzmann JA,Jelinek DF. CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell lineJ Immunol 1994;152:117–128. [pmid: 7504707]|
Keywords: therapeutic antibodies, haematopoietic malignancies, macrophages, non-Hodgkin's lymphoma, antibody-dependent cellular phagocytosis, ADCP, ADCC.
Previous Document: Rising incidence of breast cancer among female cancer survivors: implications for surveillance.
Next Document: BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma...